Natriuretic peptides in diagnosing heart failure - early assessment briefs (Alert)
Swedish Council on Technology Assessment in Health Care
Record ID 32005000117
Swedish
Authors' objectives:
This review aims to assess the extent to which measuring the blood concentration of BNP or NT-proBNP facilitate diagnosis of heart failure.
Authors' results and conclusions:
Patient benefit: Several studies have shown that natriuretic peptide testing has a high negative predictive value, which means that one can rule out with considerable certainty that a patient has heart failure. The positive predictive value of the test is not nearly as high. Hence, when elevated values were found, it was necessary to complement the test with an assessment of cardiac function to determine whether or not the patient had heart failure.
Authors' recommendations:
Moderately strong scientific evidence (Evidence grade 2) shows that BNP or NT-proBNP can be used, with good reliability, to rule out heart failure. However, evidence remains insufficient concerning the cost effectiveness of the method relative to other methods of diagnosing heart failure (Evidence grade 4).
Authors' methods:
Review
Details
Project Status:
Completed
URL for project:
http://www.sbu.se/Published
Year Published:
2005
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Sweden
MeSH Terms
- Costs and Cost Analysis
- Natriuretic Peptides
- Heart Diseases
Contact
Organisation Name:
Swedish Agency for Health Technology Assessment and Assessment of Social Services
Contact Address:
P.O. Box 3657, SE-103 59 Stockholm, Sweden. Tel: +46 8 4123200, Fax: +46 8 4113260
Contact Name:
registrator@sbu.se
Contact Email:
registrator@sbu.se
Copyright:
Swedish Council on Technology Assessment in Health Care (SBU)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.